RE: Odd25 Mar 2021 09:30
Im expecting an onlicence to astrazeneca.
not just for Wee1 (which Ive been waiting for for years to be honest, but also as a PD-1 combo with olaparib (based to Triparna Sen research last year. Olaparib needs a combo to take on keytruda, and if we can piggyback on $3bn pa sales currently not complaining.
all IMHO and a bit wishfull but been waiting years for this tie up. (oh and Olaparib also came out of ICR, so the odds they havent looked at this combo is zero).